Genevieve Losonsky, MD [clinicaltrials_resource:48c744933666277878c4b03d2c1c7d82]
Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults [clinicaltrials:NCT00192465]Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg/kg or 15 mg/kg; Children to be Followed for 90 Days After Their Last Dose of MEDI-524 [clinicaltrials:NCT00192478]A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Single Intravenous Dose of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody to Respiratory Syncytial Virus (RSV), in Otherwise Healthy Children Hospitalized With RSV Infection [clinicaltrials:NCT00192504]
overall official [clinicaltrials_vocabulary:overall-official]
Genevieve Losonsky, MD [clinicaltrials_resource:48c744933666277878c4b03d2c1c7d82]
Bio2RDF identifier
48c744933666277878c4b03d2c1c7d82
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:48c744933666277878c4b03d2c1c7d82
affiliation [clinicaltrials_vocabulary:affiliation]
last name [clinicaltrials_vocabulary:last-name]
Genevieve Losonsky, MD
role [clinicaltrials_vocabulary:role]
Study Director
identifier
clinicaltrials_resource:48c744933666277878c4b03d2c1c7d82
title
Genevieve Losonsky, MD
@en
type
label
Genevieve Losonsky, MD [clinicaltrials_resource:48c744933666277878c4b03d2c1c7d82]
@en